XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.3
Net Income (Loss) per Share
9 Months Ended
Sep. 30, 2025
Net Income (Loss) per Share [Abstract]  
Net Income (Loss) per Share

Note 9. Net Income (Loss) per Share

 

Basic income (loss) per share of common stock is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed similar to basic income (loss) per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.

 

The calculation of the Company’s diluted number of shares for the three and nine months ended September 30, 2025 is as follows:

 

   For the
three  months
ended September 30,
2025
  

For the
nine months
ended September 30,
2025 

 
Weighted average shares - basic   15,442,342    13,700,375 
           
Effect of dilutive potential common shares:          
Convertible preferred stock   34    34 
Warrants to purchase common stock   1,732,975    154,913 
           
Restricted stock awards   49,706    47,628 
           
           
           

Weighted average shares – diluted 

   17,223,257    13,902,950 

 

Warrants to purchase 357,198 shares of common stock were outstanding during the three- and nine-months period ended September 30, 2025 that were not included in the computation of diluted EPS because the exercise price was greater than the average market price of the common shares. As of September 30, 2025,  253,670 warrants expire in February 2026 and 103,528 warrants expire in February 2027. All such warrants were still outstanding at the end of September 30, 2025.

 

Options to purchase  10,036,333 shares of common stock that were outstanding during the three and nine months period ended September 30, 2025 were not included in the computation of diluted EPS because either the exercise price was greater than the average market price of the common shares or those where the exercise price was below the average market price of the common shares were antidilutive. These options, which expire between August 2026 in February 2035, were still outstanding at the end of September 30, 2025.

 

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the nine months ended September 30, 2024 included 34 shares of convertible preferred stock, 444,796 warrants to purchase common stock, 40,000 shares of restricted stock awards, and 419,988 stock options totaling to 904,818 shares.